Open AccessLuteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis
Author(s) -
Dhiraj Kumar Singh,
Sultan Tousif,
Ashima Bhaskar,
Annu Devi,
Kriti Negi,
Barnani Moitra,
Anand Ranganathan,
Ved Prakash Dwivedi,
Gobardhan Das
Publication year - 2021
Publication title -
plos pathogens
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.719
H-Index - 206
eISSN - 1553-7374
pISSN - 1553-7366
DOI - 10.1371/journal.ppat.1009805
Subject(s) - tuberculosis , luteolin , mycobacterium tuberculosis , immunity , isoniazid , medicine , immunology , regimen , rifabutin , drug resistance , antibiotics , biology , immune system , microbiology and biotechnology , clarithromycin , biochemistry , pathology , antioxidant , quercetin
Tuberculosis (TB) remains a major health problem throughout the world with one third of the population latently infected and ~1.74 million deaths annually. Current therapy consists of multiple antibiotics and a lengthy treatment regimen, which is associated with risk for the generation of drug-resistant Mycobacterium tuberculosis variants. Therefore, alternate host directed strategies that can shorten treatment length and enhance anti-TB immunity during the treatment phase are urgently needed. Here, we show that Luteolin, a plant-derived hepatoprotective immunomodulator, when administered along with isoniazid as potential host directed therapy promotes anti-TB immunity, reduces the length of TB treatment and prevents disease relapse. Luteolin also enhances long-term anti-TB immunity by promoting central memory T cell responses. Furthermore, we found that Luteolin enhances the activities of natural killer and natural killer T cells, both of which exhibit antitubercular attributes. Therefore, the addition of Luteolin to conventional antibiotic therapy may provide a means to avoid the development of drug-resistance and to improve disease outcome.